159P Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC

Autor: Merrill, N., Udager, A., Qin, A., Lagisetty, K., Aikins, M., Bao, L., Cheng, X., Goo, L., Kathawate, V., Vandenburg, B., Ulintz, P., Qin, Z., Liu, A., Serhan, H., Nagrath, S., Hsu, P., Soellner, M., Merajver, S.

Publikováno v: In ESMO Open October 2023 8(1) Supplement 5

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers

Autor: Kwang-Pil, Ko, Kim, Shana J, Huzarski, Tomasz, Gronwald, Jacek, Lubinski, Jan, Lynch, Henry T, Armel, Susan, Park, Sue K, Karlan, Beth, Singer, Christian F, Neuhausen, Susan L, Narod, Steven A, Kotsopoulos, Joanne, Snyder, C, Meschino, W, Demsky, R, Ainsworth, P, Panabaker, K, Taylor, M, Couch, F, Manoukian, S, Rappaport, C, Pasini, B, Daly, Mb, Olopade, O, Steele, L, Saal, H, Fallen, T, Wood, M, Mckinnon, W, Lemire, E, Chudley, Ae, Serfas, K, Sweet, K, Bordeleau, L, Elser, C, Panchal, S, Zakalik, D, Vadaparampil, St, Ginsburg, O, Hurst, S, Cullinane, Ca, Reilly, Re, Blum, Jl, Ross, T, Mauer, C, Kwong, A, Cybulski, C, Mccuaig, J, Merajver, S, Friedman, E, Rayson, D, Euhus, D, Foulkes, Wd, Senter, L, Tung, N, Weitzel, Jn, Eisen, A, Metcalfe, K, Eng, C, Pal, T, Evans, G, Moller, P, Rosen, B, Isaacs, C.

Tobacco smoke is an established carcinogen, but the association between tobacco smoking and cancer risk in BRCA mutation carriers is not clear. The aim of this study was to evaluate prospectively the association between tobacco smoking and cancer inc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bcac28c83a5dff304838dbdb587b6424
https://europepmc.org/articles/PMC6020833/

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

Autor: Kotsopoulos, J, Lubinski, J, Gronwald, J, Cybulski, C, Demsky, R, Neuhausen, Sl, Kim Sing, C, Tung, N, Friedman, S, Senter, L, Weitzel, J, Karlan, B, Moller, P, Sun, P, Narod, Sa, Hereditary Breast Cancer Clinical Study Group: Lynch HT, Singer, C, Eng, C, Mitchell, G, Huzarski, T, Mccuaig, J, Hughes, K, Mills, G, Ghadirian, P, Eisen, A, Gilchrist, D, Blum, Jl, Zakalik, D, Pal, T, Daly, M, Weber, B, Snyder, C, Fallen, T, Chudley, A, Lunn, J, Donenberg, T, Kurz, Rn, Saal, H, Garber, J, Rennert, G, Sweet, K, Gershoni Baruch, R, Rappaport, C, Lemire, E, Stoppa Lyonnet, D, Olopade, Oi, Merajver, S, Bordeleau, L, Cullinane, Ca, Friedman, E, Mckinnon, W, Wood, M, Rayson, D, Meschino, W, Mclennan, J, Costalas, Jw, Reilly, Re, Vadaparampil, S, Offit, K, Kauff, N, Klijn, J, Euhus, D, Kwong, A, Isaacs, C, Couch, F, Manoukian, S, Byrski, T, Elser, C, Panchal, S, Armel, S, Nanda, S, Metcalfe, K, Poll, A, Rosen, B, Foulkes, Wd, Rebbeck, T, Ainsworth, P, Robidoux, A, Warner, E, Maehle, L, Osborne, M, Evans, G, Pasini, Barbara, Ginsburg, O, Cohen, S, Bohdan, G, Jakubowska, A, Little, J.

It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30c812a4c0be0a70cb395d8b39a0ccce
http://hdl.handle.net/2318/144085

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

Autor: Gronwald, Jacek, Tung, Nadine, Foulkes, William D., Offit, Kenneth, Gershoni, Ruth, Daly, Mary, Kim-Sing, Charmaine, Olsson, Hakan, Ainsworth, Peter, Eisen, Andrea, Saal, Howard, Friedman, Eitan, Olopade, Olufunmilayo, Osborne, Michael, Weitzel, Jeffrey, Lynch, Henry, Ghadirian, Parviz, Lubinski, Jan, Sun, Ping, Narod, Steven A., Gilchrist, D., Weber, B., Rebbeck, T., Isaacs, C., Neuhausen, S., Garber, J., Karlan, B., Fishman, D., Merajver, S., McKinnon, W., Wood, M., Evans, G., Moller, P., Pasini, B., Sweet, K., Eng, C., Rennert, G., Couch, F., McLennan, J., Provencher, D.

Publikováno v: Gronwald, J, Tung, N, Foulkes, W D, Offit, K, Gershoni, R, Daly, M, Kim-Sing, C, Olsson, H, Ainsworth, P, Eisen, A, Saal, H, Friedman, E, Olopade, O, Osborne, M, Weitzel, J, Lynch, H, Ghadirian, P, Lubinski, J, Sun, P, Narod, S A, Gilchrist, D, Weber, B, Rebbeck, T, Isaacs, C, Neuhausen, S, Garber, J, Karlan, B, Fishman, D, Merajver, S, McKinnon, W, Wood, M, Evans, G, Moller, P, Pasini, B, Sweet, K, Eng, C, Rennert, G, Couch, F, McLennan, J & Provencher, D 2006, ' Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers : An update ', International Journal of Cancer, vol. 118, no. 9, pp. 2281-2284 . https://doi.org/10.1002/ijc.21536

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is approximately 30%. It has been shown that both tamoxifen and ooph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06079990350de0bfb67ccd450b3b9e19
https://pubmed.ncbi.nlm.nih.gov/16331614